Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Colomer

Showing results (21-30 of 92) with videos related to

Pageof 10
Sort By:
The International Journal of Biological Markers|September 1, 1986
Serum CA 15.3 levels in patients with non-tumoral diseases, and establishment of a threshold for tumoral activity. Results in 1219 patientsA Ruibal, J Genollá, M Rosell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2003
Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumorsD Castellano, R Hitt, E Ciruelos, et al.
Cell Proliferation|January 24, 2008
Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cellsA Vazquez-Martin, R Colomer, J Brunet, et al.
Bulletin Du Cancer|January 1, 1986
Serum CA 15.3 levels in patients with general pathology and malignant diseases (excluding breast cancer)A Ruibal, G Encabo, J Genollá, et al.
The International Journal of Biological Markers|May 1, 1986
Circulating CA 15.3 levels in breast cancer. Our present experienceR Colomer, A Ruibal, M Navarro, et al.
Clinical Chemistry|May 1, 1986
Concentration of myelin basic protein in cerebrospinal fluid in prognosis of multiple sclerosisJ Matias-Guiu, A Ruibal, J M Martinez-Vazquez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 20, 2008
Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cellsA Vazquez-Martin, C Oliveras-Ferraros, R Colomer, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|September 13, 2001
Prognostic value of cytosolic p53 protein in breast cancerS Montero, C Guzmán, C Vargas, et al.
Anticancer Research|July 1, 1986
CA 15.3: early results of a new breast cancer markerR Colomer, L A Sole, M Navarro, et al.
British Journal of Cancer|January 1, 1997
Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinomaR Colomer, J Aparicio, S Montero, et al.
Pageof 10

Showing results (21-30 of 92) with videos related to

Sort By:
Pageof 10
The International Journal of Biological Markers|September 1, 1986
Serum CA 15.3 levels in patients with non-tumoral diseases, and establishment of a threshold for tumoral activity. Results in 1219 patientsA Ruibal, J Genollá, M Rosell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2003
Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumorsD Castellano, R Hitt, E Ciruelos, et al.
Cell Proliferation|January 24, 2008
Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cellsA Vazquez-Martin, R Colomer, J Brunet, et al.
Bulletin Du Cancer|January 1, 1986
Serum CA 15.3 levels in patients with general pathology and malignant diseases (excluding breast cancer)A Ruibal, G Encabo, J Genollá, et al.
The International Journal of Biological Markers|May 1, 1986
Circulating CA 15.3 levels in breast cancer. Our present experienceR Colomer, A Ruibal, M Navarro, et al.
Clinical Chemistry|May 1, 1986
Concentration of myelin basic protein in cerebrospinal fluid in prognosis of multiple sclerosisJ Matias-Guiu, A Ruibal, J M Martinez-Vazquez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 20, 2008
Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cellsA Vazquez-Martin, C Oliveras-Ferraros, R Colomer, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|September 13, 2001
Prognostic value of cytosolic p53 protein in breast cancerS Montero, C Guzmán, C Vargas, et al.
Anticancer Research|July 1, 1986
CA 15.3: early results of a new breast cancer markerR Colomer, L A Sole, M Navarro, et al.
British Journal of Cancer|January 1, 1997
Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinomaR Colomer, J Aparicio, S Montero, et al.
Pageof 10